Value of dipyridamole with first pass radionuclide ventriculography in assessment of coronary artery disease

N. Zafrir, R. Bassevitch, I. Teplitsky, U. Gabbay, J. Sulkes, E. Lubin

Research output: Contribution to journalArticlepeer-review

Abstract

The use of dipyridamole with first pass radionuclide ventriculography for detecting coronary artery disease is described for the first time. Fifteen patients with normal coronary arteries demonstrated a mean increase in ejection fraction after dipyridamole, while 41 patients with severe coronary artery disease (> 70% stenosis) demonstrated a mean decrease in ejection fraction (6.3 ± 6%, -6.5 ± 6%, respectively; p < 0.05). Mean wall motion score was zero in the normal group and 1.27 ± 1.13 in the abnormal group. End-diastolic volume did not change significantly in either group. However, end-systolic volume decreased in the normal group (p = 0.019) and markedly increased in the abnormal group (p = 0.0001). The sensitivity of this technique was 73% and specificity 93%. However, the sensitivity increased to 89% in multivessel disease. Dipyridamole has an effect on the systolic performance in patients with marked coronary artery disease.

Original languageEnglish
Pages (from-to)366-372
Number of pages7
JournalAmerican Journal of Noninvasive Cardiology
Volume8
Issue number6
DOIs
StatePublished - 1994
Externally publishedYes

Keywords

  • Coronary artery disease
  • Dipyridamole
  • First pass radionuclide ventriculography

Fingerprint

Dive into the research topics of 'Value of dipyridamole with first pass radionuclide ventriculography in assessment of coronary artery disease'. Together they form a unique fingerprint.

Cite this